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B7h, a Novel Costimulatory Homolog
of B7.1 and B7.2, Is Induced by TNFa
(Fiers, 1993). In an effort to identify TNFa-induced genes
that were specifically regulated by NF-kB/Rel transcrip-
tion factors, we initiated a subtractive screen using 3T3
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cell lines generated from wild-type and RelA2/2 embry-Cancer Research Laboratory
onic fibroblasts (Beg and Baltimore, 1996). Surprisingly,Molecular and Cell Biology Department
one of the novel genes we identified was a close homo-University of California, Berkeley
log of the B7.1 and B7.2 costimulatory ligands ex-Berkeley, California 94720
pressed on antigen-presenting cells.
Generation of an effective immune response by T cells
requires at least two signals from antigen-presentingSummary
cells: one mediated by specific antigen bound to MHC
molecules and a second antigen-independent signalIn a screen to identify genes induced by NF-kB/Rel
mediated by costimulatory ligands (for review seetranscription factors, we cloned a novel gene, b7h,
Lenschow et al., 1996; Chambers and Allison, 1999). Thethat is a close homolog of B7 costimulatory ligands
primary costimulatory receptor expressed on T cells isexpressed on antigen-presenting cells. B7h can costim-
CD28. Interaction of CD28 with either of its ligands,ulate proliferation of purified T cells through a recep-
B7.1 or B7.2, results in enhanced T cell proliferation andtor on T cells distinct from CD28 or CTLA-4. Surpris-
cytokine secretion. Interactions of either B7.1 or B7.2ingly, although B7h is expressed in unstimulated B
with CTLA-4, a homolog of CD28 expressed on T cells,cells, its expression is induced in both 3T3 cells and
results in inhibition of T cell responses (Walunas et al.,embryonic fibroblasts treated with TNFa, and it is
1994; Krummel and Allison, 1995). Recently, a third co-upregulated in nonlymphoid tissues of mice treated
stimulatory receptor, ICOS, was identified that is a closewith LPS, a potent activator of TNFa. These data define
structural homolog of CD28 and CTLA-4 (Hutloff et al.,a novel costimulatory ligand for T cells and suggest
1999). ICOS is induced on activated T cells and canthat induction of B7h by TNFa may function as a mech-
costimulate T cell proliferation and a different spectrumanism to directly augment recognition of self during
of T cell cytokine production, but it does not appear toinflammation.
act through binding to B7.1 or B7.2.
B7.1 and B7.2 are related immunoglobulin supergeneIntroduction
family members that are expressed by multiple cell types
involved in antigen presentation (for review see McAdamNF-kB/Rel transcription factors are key regulators of
et al., 1998). Both B7.1 and B7.2 are constitutively ex-proinflammatory genes (for review see Baeuerle, 1998;
pressed on dendritic cells and are upregulated on mono-Ghosh et al., 1998; Sha, 1998). Because NF-kB/Rel tran-
cytes, macrophages, B cells, and T cells following acti-
scription factors are uniquely positioned downstream
vation (Hathcock et al., 1994; Inaba et al., 1994). The
of multiple innate and adaptive signaling pathways, they
upregulation on cells activated by various stimuli differs
seem ideally placed to integrate and coordinate innate in terms of both the kinetics and density of expression
and adaptive signals required for formation of produc- of B7.1 and B7.2. B cells and monocytes, for example,
tive immune responses. In an effort to explore how this upregulate B7.2 expression within 24 hr following activa-
integration might be regulated by these transcription tion with LPS, whereas B7.1 can only be detected 48 hr
factors, we initiated a screen to identify NF-kB/Rel- after activation, with the maximal cell surface expression
dependent genes that are induced by the inflammatory being much less than observed with B7.2 (Freedman et
cytokine TNFa. al., 1991; Lenschow et al., 1993; Hathcock et al., 1994).
TNFa is a potent inflammatory cytokine secreted prin- The complex regulation of B7.1 and B7.2 expression
cipally by macrophages, but also by activated CD41 T is consistent with these costimulatory ligands function-
cells, that has been implicated in the pathogenesis of ing as critical regulatory molecules for control of immune
a number of autoimmune conditions (for review see Vas- responses and has spurred considerable investigation
salli, 1992; Feldmann et al., 1998). TNFa is both tran- of how the costimulatory environment may be altered
scriptionally activated by NF-kB/Rel factors and leads or augmented during infection, inflammation, and auto-
to activation of these transcription factors through TNFa immune conditions. We report here the identification of
receptors (Collart et al., 1990; Shakhov et al., 1990; Hsu a novel T cell costimulatory ligand, B7h, that is a third
et al., 1995). This intimate relationship between TNFa member of the B7 family based on its amino acid homol-
and NF-kB/Rel transcription factors is highlighted by ogy to B7.1 and B7.2. B7h interacts with a receptor on
the recent demonstration that the embryonic lethality activated T cells distinct from CD28 or CTLA-4, and it
observed in RelA2/2 mice is rescued by crosses to costimulates proliferation of T cells. B7h is expressed
TNFa2/2 mice (Doi et al., 1999). TNFa is known to induce in B cells and is most highly expressed in peripheral
many gene products involved in inflammation, tissue lymphoid tissues of mice. Surprisingly, B7h expression
repair, immune response, apoptosis, and hematopoiesis was induced in 3T3 cells and embryonic fibroblasts
treated with TNFa and was upregulated in nonlymphoid
tissues of mice injected with LPS, a potent inducer of* To whom correspondence should be addressed (e-mail: bsha@
uclink4.berkeley.edu). TNFa (Beutler et al., 1986; Kornbluth and Edgington,
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Figure 1. The D30 cDNA Fragment Obtained
by RDA Corresponds to a Gene that Is In-
duced by TNFa and Dependent on RelA Acti-
vation
RDA was performed using polyA1 RNA iso-
lated from RelA1/1 and RelA2/2 3T3 cells that
were treated with TNFa (10 ng/ml) for 1.5 hr.
RelA1/1 3T3 cells were used as the tester
population in order to isolate cDNAs that
were dependent on RelA activation.
(A) D30 is successively enriched after each
round of RDA selection in the difference
products DP1, DP2, and DP3. Difference prod-
ucts were electrophoresed on an agarose
gel, transferred to a Hybond-N1 membrane
(Amersham), and hybridized with either a D30
or control GAPDH probe.
(B) D30 is expressed in cDNA prepared from
RelA1/1 but not RelA2/2 3T3 cells. Equivalent
amounts of the original cDNA representations
from 3T3 cells treated with TNFa for 1.5 hr
were blotted and hybridized with either a D30
or control b-actin probe.
(C) D30 corresponds to a gene that is induced
by TNFa and dependent on RelA for expres-
sion. Total RNA (15 mg) prepared from 3T3
cells was analyzed for D30 expression using
RNase protection probes for D30 and b-actin.
1986). These data suggest a distinct role for B7h as the D30 cDNA fragment, we examined expression of
this candidate gene in RNA samples prepared from 3T3a costimulatory ligand that can be transiently induced
on non-antigen-presenting cells by inflammatory cyto- cells before and after treatment with TNFa (Figure 1C).
In both untreated wild-type and RelA2/2 3T3 cells, thekines. Thus, induction of B7h by TNFa may function as
a direct mechanism by which recognition of self by T gene corresponding to the D30 cDNA fragment was not
expressed in the absence of TNFa. When these 3T3cells is enhanced in local tissues during an inflammatory
response. cells were treated with TNFa, transcription was induced
in wild-type 3T3 cells but not in RelA2/2 3T3 cells. These
results demonstrate that the D30 cDNA fragment corre-Results
sponded to a gene that was not normally expressed in
3T3 cells, but which could be induced by TNFa treat-Identification of a TNFa-Induced Gene Dependent
on NF-kB/Rel Activation ment, and required activation of the RelA member of
the NF-kB/Rel transcription factor family for expression.To identify TNFa-induced genes regulated by the RelA
transcription factor, we performed cDNA subtraction by
representational difference analysis (RDA) (Lisitsyn and
Wigler, 1993; Hubank and Schatz, 1994). RDA was per- B7h Encodes for a Protein with Homology to B7
Costimulatory Ligandsformed using TNFa-treated 3T3 cells that were derived
from RelA2/2 and wild-type RelA1/1 embryonic fibro- Because the D30 cDNA fragment did not correspond
to a previously identified gene, we screened a murineblasts (Beg and Baltimore, 1996). Wild-type 3T3 cells
were used to prepare tester representations that were thymus cDNA library with a D30 probe and isolated a
2.7 kb cDNA clone. This clone size was consistent withsubtracted with an excess of driver representations pre-
pared from RelA2/2 3T3 cells. After three rounds of en- the single mRNA band of approximately 2.8 kb that we
observed in Northern blots of mRNA isolated from TNFa-richment for cDNA fragments that were differentially ex-
pressed in wild-type 3T3 cells, the third difference treated 3T3 cells and from spleen tissue that was probed
with the D30 cDNA fragment (data not shown). Sequenceproduct was subcloned and individual cDNA enzyme
fragments were characterized. One of these cDNA frag- analysis of the 2.7 kb cDNA clone revealed that the 59
end contained an open reading frame for a 322 aminoments, D30, did not correspond to a known gene or
expressed sequence tag, was successively enriched in acid protein that we termed B7h, for B7 homologous
protein (Figure 2).difference products 1, 2, and 3 (Figure 1A), and was
expressed in the original representation from wild-type, The b7h cDNA encoded for a type I transmembrane
protein that was an immunoglobulin superfamily mem-but not RelA2/2, 3T3 cells (Figure 1B).
Using an RNase protection probe corresponding to ber. The domain structure of B7h was homologous to
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Figure 2. The D30 Fragment Corresponds to a cDNA Encoding a Protein, B7h, Homologous to B7 Costimulatory Ligands
DNA sequence of the b7h cDNA is shown with the coding region in bold. The location of the D30 cDNA fragment in the 39-untranslated region
is underlined. The location of a second RNase protection probe used in Figures 6 and 7 is underlined in the coding region.
B7 costimulatory ligands and contained a signal pep- B7h Interacts with Receptor(s) on Activated T Cells
Distinct from CTLA4 or CD28tide, two extracellular immunoglobulin-like domains, a
transmembrane region, and a short cytoplasmic tail (Fig- We confirmed that the b7h cDNA encoded for a trans-
membrane receptor by first examining the intracellularure 3). Numerous potential N-linked glycosylation sites
were identified in the extracellular portion of B7h, con- localization of a B7h-GFP fusion protein, generated by
fusing the N terminus of green fluorescent protein (GFP)sistent with it being a transmembrane protein. The cyste-
ine residues that are conserved in both the V- and C-like to the C terminus of the putative cytoplasmic domain
of B7h. CHO cells were infected with retroviral vectorsimmunoglobulin domains of B7.1 and B7.2 were also
conserved in B7h. The amino acid identities between expressing either control GFP or the B7h-GFP fusion
protein. When visualized by fluorescence microscopy,B7h and B7.2 and between B7h and B7.1 were both
20%. Since B7.1 and B7.2 possess the same degree of the B7h-GFP fusion protein was localized to the surface
of cells, whereas the GFP expressed by control vectoramino acid identity, B7h is a B7 family member that is as
closely related to B7.1 and B7.2 as these costimulatory was seen distributed throughout cells (Figure 4A). To
confirm that B7h was actually expressed on the cellligands are to each other (Freeman et al., 1991, 1993).
Figure 3. B7h Is a Member of the B7 Family of Costimulatory Ligands
Amino acid sequence alignment of B7h with murine B7.1 and B7.2 obtained using the Clustal-W algorithm with BLOSUM 30 matrix (MacVector,
Oxford Molecular Group). Identical amino acid residues are shaded, conserved residues are boxed, and conserved cysteine residues are
shown in black. Predicted signal peptide, Ig V-like and C-like domains, and the transmembrane region for B7h are indicated.
Immunity
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Figure 4. B7h Is a Transmembrane Ligand for a Receptor Expressed on Activated T Cells Distinct from CTLA-4 or CD28
(A) B7h localizes to the cell surface. CHO cells infected with retroviral vectors expressing either a B7h-GFP fusion protein or GFP alone were
imaged by confocal fluorescence microscopy. GFP fluorescence is shown in white.
(B) B7h is a transmembrane protein. Whole cell lysates of CHO cells expressing either B7h-GFP or GFP were immunoblotted with an anti-
GFP antibody. Intact CHO cells were cell surface labeled with biotin, lysed in 0.5% NP-40-containing buffer, immunoprecipitated with an anti-
GFP antibody, and immunoblotted with streptavidin-HRP.
(C) Expression of B7h on CHO cells induces binding of activated T cells. Activated T and B cells labeled with 3H-thymidine were added to
96-well plates containing confluent monolayers of CHO cells expressing either B7h or GFP. Plates were briefly spun and then incubated at
378C for 45 min. Following five washes with PBS, 3H-thymidine in wells was measured. Binding is presented as a percentage of input counts.
Error bars indicate standard deviation of triplicate cultures.
(D) B7h-Ig binds to activated T cells. Resting and activated T and B cells were stained with a B7h-Ig fusion protein (z0.1 mg) and analyzed
by flow cytometry. T cells were activated with PMA (10 ng/ml) and ionomycin (1 mg/ml) for the indicated times. B cells were activated with
LPS (30 mg/ml). Specific staining of activated T cells was not inhibitable by addition of CTLA-4-Ig (5 mg). Control background staining is shown
shaded in grey.
(E) B7h does not interact with CD28 or CTLA-4. 3T3 cells alone or expressing either B7.2 or B7h were stained with CTLA-4-Ig (1 mg) and
CD28-Ig (2 mg) fusion proteins and analyzed by flow cytometry. Expression of B7.2 was monitored using an IRES-GFP marker, and expression
of B7h was monitored using a B7h-GFP fusion protein.
surface, intact CHO cells expressing either GFP or B7h- Given the striking homology between B7h and B7
costimulatory ligands, we next examined whether ex-GFP were biotinylated, and then lysates of these CHO
cells were immunoprecipitated with an anti-GFP antibody. pression of B7h on CHO cells could result in formation
of cell surface contacts with T cells. We observed thatImmunoblotting of immunoprecipitates with streptavidin-
HRP demonstrated that B7h-GFP was biotinylated, con- approximately 3- to 5-fold more activated T cells bound
to CHO cells expressing B7h than to control CHO cellssistent with its localization by microscopy (Figure 4B).
In contrast, intracellular GFP was not biotinylated but expressing GFP. To quantitate this binding of T cells,
activated T cells labeled with 3H-thymidine were platedcould be detected by immunoblotting whole cell lysates
with an anti-GFP antibody. These results demonstrate on CHO cells, and then washed to remove nonadherent
cells. A 4-fold greater number of activated T cells boundthat B7h is a transmembrane molecule expressed on
the cell surface. to CHO-B7h cells over CHO-GFP cells (Figure 4C). This
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interaction was specific to activated T cells, as activated or GFP. Again we observed that B7h could costimulate
proliferation of T cells at submitogenic doses of OVAB cells demonstrated no preferential association with
B7h expressing CHO cells. These results indicate that peptide that induced no proliferation of T cells plated
alone or on 3T3 cells expressing either I-Ad or I-Ad andB7h is a membrane ligand for cell surface receptor(s)
expressed on activated T cells. GFP (Figure 5B). Addition of CTLA-4-Ig to block interac-
tions between CD28 and B7 ligands had no effect onTo test whether the physical interaction between B7h
and activated T cells occurred via CD28 or CTLA4 costim- the ability of 3T3 cells expressing B7h to costimulate T
cell proliferation under conditions in which costimulationulatory receptors, we performed flow cytometric anal-
ysis of T cells using a B7h-Ig fusion protein generated by B7.2-expressing 3T3 cells was inhibited (Figure 5C).
These data indicate that B7h costimulates T cell prolifer-by fusing the putative binding domains of B7h to the
CH2-CH3 domains of mouse IgG1. B7h-Ig bound specif- ation via a CD28-independent mechanism.
ically to the surface of activated T cells but not to the
surface of naive T cells or resting or activated B cells Specific Induction of B7h by TNFa
(Figure 4D). This binding was not blocked by addition The observation that TNFa treatment of 3T3 cells re-
of CTLA-4-Ig, indicating that B7h bound to a receptor sulted in expression of a costimulatory ligand for T cells
induced on activated T cells distinct from CTLA-4 or prompted us to examine whether other cytokines or
CD28. inflammatory stimuli could also induce B7h expression.
Further evidence that B7h does not interact with CD28 Analysis using a second RNase protection probe corre-
and CTLA-4 coreceptors on T cells came from reciprocal sponding to the coding region of B7h demonstrated
experiments in which bulk 3T3 cell lines expressing cell that treatment of 3T3 cells with TNFa rapidly induced
surface B7h were analyzed by flow cytometric analysis expression of B7h that was maximal at 16 hr and ap-
for binding to CTLA-4-Ig and CD28-Ig fusion proteins, peared self-limiting by 24 hr (Figure 6A). Treatment of
comprised of the binding domains of CTLA-4 and CD28 3T3 cells with IFNg, however, did not lead to induction
linked to human immunoglobulin constant regions (Fig- of B7h under conditions in which class I MHC was in-
ure 4E). 3T3 cells, which normally do not express B7.1 duced, nor did it synergize with TNFa in induction of
or B7.2, were transduced with retroviral vectors for B7h B7h expression (Figure 6B). B7h was also not induced
and B7.2 at 100% efficiency with retroviral vectors, by either IL-1a or LPS treatment alone, indicating that
based on GFP marker expression. Because of the the induction of B7h expression by TNFa was highly
greater affinity of CTLA-4 for binding to B7 members specific.
(van der Merwe et al., 1997), 3T3 cells expressing B7.2 Although B7.1 and B7.2 are expressed in vivo on im-
stained much more strongly with CTLA-4-Ig than with mune cells involved in antigen presentation, these mole-
CD28-Ig (Figure 4E). In contrast, 3T3 cells expressing cules are constitutively expressed on certain cell lines,
B7h did not show any specific staining with either CTLA- such as sublines of L cells, that were originally derived
4-Ig or CD28-Ig. These results are consistent with the from primary cells of non-antigen-presenting origin.
staining results with B7h-Ig that indicate that B7h does Consequently, we wanted to examine whether our ob-
not bind or interact with either CD28 or CTLA-4 recep- servation that TNFa could induce B7h expression was
tors. Thus, the interaction of B7h with activated T cells a property peculiar to immortalized 3T3 cell lines. Using
occurs by a receptor distinct from CD28 or CTLA-4. early passage embryonic fibroblasts prepared from day
12 embryos, we observed that these primary embryonic
fibroblasts did not express B7h and that TNFa treatmentB7h Functions as a Costimulatory Ligand
induced expression of B7h in these cells (Figure 6C).for T Cells
This result indicates that induction of B7h expression byGiven the sequence homology to B7 costimulatory li-
TNFa is a property of both primary embryonic fibroblastsgands and the interaction of B7h with activated T cells,
and 3T3 cell lines derived from these fibroblasts.we next examined whether B7h could function as a co-
stimulatory ligand for T cells. We first tested whether
B7h could costimulate T cell proliferation in trans, by LPS-Induced Expression of B7h
in Nonlymphoid Tissuesexamining the ability of 3T3 cells expressing either B7h,
GFP, or B7.2 to costimulate proliferation of purified To explore the potential physiological relevance of the
ability of TNFa to induce B7h expression, the expressionlymph node T cells in plates coated with different
amounts of anti-TCR antibodies (Figure 5A). B7.2- pattern of B7h was examined in tissues of normal mice
and in tissues of mice challenged with LPS, a potentexpressing 3T3 cells resulted in costimulation of T cell
proliferation at submitogenic doses of anti-TCR antibod- inducer of TNFa (Beutler et al., 1985; Mathison et al.,
1988). In normal mice, B7h was most highly expressedies that did not result in proliferation of T cells incubated
with GFP-expressing 3T3 cells. B7h-expressing 3T3 in peripheral lymphoid tissues, spleen, and lymph node
(Figure 7A). Constitutive expression of B7h was alsocells also costimulated T cell proliferation at submito-
genic doses of anti-TCR antibodies, although the costim- observed in splenocytes and in B cells purified from
spleen. Lower levels of B7h expression were found inulatory effect required higher doses of anti-TCR anti-
bodies than seen with B7.2-expresing 3T3 cells. Thus, many nonlymphoid tissues such as kidney, liver, perito-
neum, and testes. Intermediate levels of B7h expressionB7h could costimulate proliferation of T cells in trans.
To test the ability of B7h to costimulate T cell prolifera- were observed in lung and thymus.
We next examined by an RNase protection assaytion in cis, purified transgenic T cells from DO11.10
transgenic TCR mice were plated on 3T3 cells express- whether B7h expression was induced in tissues of mice
at different time points following intraperitoneal injectioning I-Ad alone or in combination with either B7h, B7.2,
Immunity
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Figure 5. B7h Costimulates T Cell Proliferation
Proliferation was measured by 3H-thymidine incorporation in cultures pulsed in the last 18 hr of a 72 hr incubation with 3H-thymidine (1 mCi/
well [6.7 Ci/mmol] in [A and B], 2 mCi/well [20 Ci/mmol] in [C]).
(A) Proliferation of lymph node T cells is costimulated in vitro by 3T3 cells expressing B7h. Purified T cells (105) were cultured in complete
media on plates coated with the indicated concentrations of anti-CD3 (mAb 500A2) and 6 3 103 3T3 cells expressing either B7.2, B7h, or
GFP. Proliferation of irradiated 3T3 cells in the absence of anti-CD3 has been subtracted from presented values, which represent averages
of triplicate cultures that varied by no more than 35%.
(B) Proliferation of DO11.10 transgenic T cells is costimulated in vitro by 3T3 cells expressing I-Ad and B7h. Purified D011.10 transgenic T
cells (5 3 104) were plated alone or on confluent 3T3 cells (12 3 103) expressing I-Ad alone or in combination with B7.2, B7h, or GFP. OVA
peptide was added to cultures at the indicated concentrations. Proliferation of irradiated/mitomycin-C-treated 3T3 cells in the absence of
peptide has been subtracted from presented values. Error bars indicate standard deviation of triplicate cultures.
(C) Costimulation of T cell proliferation by B7h is not dependent on interactions with CD28 or CTLA-4. Under conditions described in (B),
CTLA-4-Ig (5 mg/ml) was added to purified D011.10 transgenic T cells plated alone or on confluent 3T3 cells expressing I-Ad with B7.2, B7h,
or GFP. Data was treated as described in (B). Normalized data for inhibition of 3H-thymidine incorporation by of CTLA-4-Ig is shown at three
submitogenic concentrations of OVA peptide where both B7h and B7.2 costimulate T cell proliferation.
of LPS (Figure 7B). Of four nonlymphoid tissues exam- These results demonstrate that in an acute inflamma-
tory response where TNFa is secreted, B7h was upregu-ined, testes, kidney, and peritoneum showed induction
of B7h expression that was maximal at 6 hr after LPS lated in nonlymphoid tissues. While we cannot identify
the cellular source of LPS-induced B7h expression ininjection. The fourth nonlymphoid tissue, liver, showed
no induction of B7h expression. In spleen, where B7h these nonlymphoid tissues, it is unlikely that this in-
crease in B7h expression arose from blood contamina-was basally expressed, a decrease in B7h expression
was observed. This lack of induction of B7h expression tion, since no induction of B7h expression was observed
in liver, a highly vascular tissue. Further, the maximalin spleen was consistent with our observation that in
vitro cultures of splenocytes treated with either TNFa induced levels of B7h expression in nonlymphoid tissues
were as high as 20% of the levels observed in the sameor LPS did not result in induction of B7h expression
(data not shown). amount of RNA from spleen. In these same tissues, the
levels of B7.2 expression were not detectable relativeThe induced expression of B7h in tissues of LPS-
treated mice differed in two important respects from the to the levels observed in spleen.
expression pattern of B7.2 in the same tissues. First, in
contrast to B7h expression, B7.2 expression was rapidly Discussion
induced in the spleens of mice injected with LPS. This
result was consistent with the ability of LPS to induce We have identified a novel T cell costimulatory ligand,
B7h, that is a close homolog of the B7.1 and B7.2 costim-B7.2 expression in B cells (Hathcock et al., 1994; Inaba
et al., 1994). Second, in nonlymphoid tissues where we ulatory ligands expressed on antigen-presenting cells.
This molecule costimulates T cell proliferation via aobserved clear induction of B7h expression, no induc-
tion of B7.2 expression was seen. CD28-independent mechanism. It is expressed in B
B7h, a Novel Costimulatory Ligand, Induced by TNFa
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induction of B7h expression by TNFa is rapid, highly
specific, and dependent upon activation of RelA. Al-
though B7.1 and B7.2 are largely confined to expression
on antigen-presenting cells, it has been reported that
expression of B7.1 but not B7.2 can be induced after
treatment with a combination of IFNg and TNFa using
short-term fibroblast-like cell lines (FCLs) derived from
pancreas, muscle, and skin (Pechhold et al., 1997). The
induction of B7h we report here differs from the induc-
tion of B7.1 observed in short-term fibroblast cultures
in several important respects. First, constitutive B7.1
expression was observed on most FCLs even in the
absence of cytokines. In contrast, no expression of B7h
was detected in primary embryonic fibroblasts or 3T3
cells in the absence of cytokines. Second, the upregula-
tion of B7.1 expression occurred over several days,
whereas the induction of B7h expression occurred rap-
idly within 1 hr after cytokine treatment. Finally, the
upregulation of B7.1 expression required treatment with
both IFNg and TNFa. In contrast, the induction of B7h
expression was induced by TNFa treatment alone, indi-
cating that cytokine products of activated T cells or NK
cells were not necessary for induction of B7h ex-
pression.
Ectopic expression of costimulatory ligands on non-
antigen-presenting cells has been shown to result in
heightened immune responses and, in some cases, in
an increased propensity to develop autoimmunity. Im-
munization with tumor cells transfected with B7 ligands
can result in antigen-specific T cell responses of suffi-
cient magnitude to allow rejection of parental tumors
Figure 6. B7h Is Specifically Induced in 3T3 and Embryonic Fibro- upon rechallenge (Chen et al., 1992; Townsend and Alli-
blasts by TNFa son, 1993). In transgenic models where B7 ligands were
Total cellular RNAs (15 mg) were prepared and analyzed for expres- expressed on parenchymal cells of different tissues, ani-
sion of B7h and b-actin by an RNase protection assay. mals had amplified host immune responses and in some
(A) 3T3 cells were treated with TNFa (10 ng/ml) and analyzed for models were more prone to developing local inflamma-
B7h expression at the indicated time points.
tion and frank autoimmunity (Guerder et al., 1988; Harlan(B) 3T3 cells were treated with IFNg (50 U/ml) with and without TNFa
et al., 1994; Nasir et al., 1994; Williams et al., 1994).(10 ng/ml) for 1.5 hr. Cell surface expression of class I MHC Kb was
Our results demonstrating rapid induction of B7h ex-upregulated on 3T3 cells at the IFNg concentrations used (data not
shown). 3T3 cells were treated with IL-1a (10 ng/ml) or LPS (100 pression in nonlymphoid tissues of mice treated with
mg/ml) for 8 hr. LPS are consistent with the induction of B7h expression
(C) Embryonic fibroblasts were treated with and without TNFa (10 we observed in TNFa-treated 3T3 cells and embryonic
ng/ml) for 4 hr. fibroblasts and indicate that inflammatory cytokines
elicited in vivo can also induce B7h expression in a wide
variety of tissues. While we cannot determine whether
cells, and in vivo it is highly expressed in peripheral the induced B7h expression we observed resulted from
lymphoid tissues. One candidate for the interacting part- parenchymal cells or from resident or recruited antigen-
ner of B7h on T cells is the recently described ICOS presenting cells, the differential upregulation of B7h in
molecule that is a close homolog of CD28 and CTLA-4 local tissues (but not spleen) was striking when com-
(Hutloff et al., 1999). Because ICOS is expressed only pared to upregulation of B7.2, which was induced in
on activated T cells, the ability of ICOS to costimulate T spleen but was only detectable at very low levels in the
cell proliferation and cytokine release is more restricted nonlymphoid tissues examined. This differential regula-
than CD28, which is expressed on resting T cells. Thus, tion of B7h expression in response to LPS treatment
the costimulatory activity of ICOS is observed only suggests that induced B7h may play an important role
above the threshold of T cell activation where ICOS in mediating local tissue responses to inflammatory con-
becomes expressed. Our studies with B7h are consis- ditions.
tent with a partner molecule with properties similar to The ability of inflammatory cytokines to upregulate
ICOS, since B7h binds to a receptor on activated T cells the local costimulatory environment has been reported
and costimulates T cell proliferation in a narrower range in a variety of different experimental systems. For in-
of TCR activation than B7.2. stance, fibroblasts transfected with viral proteins were
A striking property of B7h, which suggests a functional capable of directly inducing antiviral cytotoxic T cell
role quite distinct from B7.1 and B7.2, is its ability to responses in vivo without involvement of host APCs,
be induced in 3T3 cells and embryonic fibroblasts in but only when the fibroblasts were placed in the cyto-
kine-rich environment of lymphoid tissues (Kundig etresponse to TNFa treatment. This cytokine-mediated
Immunity
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Figure 7. B7h Expression in Normal Mice and Mice Injected with LPS
Total cellular RNA (15 mg) prepared from tissues of normal mice or mice injected intraperitoneally with LPS were analyzed for B7h, B7.2, and
b-actin expression by RNase protection analysis.
(A) B7h is highly expressed in peripheral lymphoid tissues of normal C57BL/6 mice and in splenocytes and purified splenic B cells.
(B) B7h expression is upregulated in nonlymphoid tissues of mice injected with LPS. (C57BL/6 3 CBA)F1 mice were injected intraperitoneally
with 700 mg of LPS (Sigma) and tissues were harvested at 6, 12, and 24 hr timepoints following injection; controls not receiving LPS are shown
as the 0 hr timepoint. Fold induction of B7h and B7.2 expression over the 0 hr timepoint for each tissue were quantitated by Phosphorimager
and normalized to b-actin expression. Each RNA sample was simultaneously analyzed with a combination of three RNase protection probes
for B7h, B7.2, and b-actin. Equivalent exposure times of autoradiographs for both B7h and B7.2 probes and tissues are shown; a shorter
exposure time is shown for b-actin due to higher expression.
BamHI BSSKII(-) vector (Stratagene) and checked for differentialal., 1995). Local expression of B7.1 has been observed
expression against original cDNA representations. Positive clonesby RT±PCR and immunohistochemistry in lesions from
were sequenced and RNase protection probes were used to confirmtissues of patients with T cell±mediated inflammatory
differential expression against RNAs prepared from 3T3 cells.
skin diseases and other autoimmune disorders (Simon
et al., 1994; Windhagen et al., 1995; Imagawa et al., Cloning and Retroviruses
The b7h cDNA clone was isolated from a murine thymus cDNA1996).
library (Stratagene) and sequenced using an ABI Prism 310 GeneticOur identification of B7h as a costimulatory ligand
Analyzer. A B7h-GFP fusion protein was created by subcloning athat is constitutively expressed in B cells but is also
SalI±BamHI insert of B7h, generated by PCR using the oligonucleo-capable of being induced by TNFa through activation
tides 59-ACGCGTCGACCATGCAGCTAAAGTGTCCCTGTT-39 and
of proinflammatory NF-kB/Rel factors suggests a simple 59-GGCGGATCCGGCGTGGTCTGTAAGTTCAAGCTG-39, into the
mechanism that may contribute to how inflammatory pEGFP-N3 mammalian expression vector (Clontech). A SalI±NotI
insert corresponding to this B7h-GFP fusion protein was subclonedcytokines augment immune responses. Given the higher
into a murine stem cell virus (MSCV) retroviral vector (Hawley et al.,threshold of TCR activation required for costimulation
1994). To create a B7h-Ig fusion protein, a second PCR insert ofby B7h and the self-limited induction we report here,
B7h was generated using the same 59 oligonucleotide and one corre-we speculate that one physiological role of B7h may be
sponding to the end of the C-like Ig domain, 59-GGCGGATCCGCGT
to augment immune responses in nonlymphoid tissues TATTTCCAGTGAAACTTTCTGCCTG-39, and ligated in frame to the
by costimulation of T cells after their primary activation CH2-CH3 domain of mouse IgG1 at the Pro227 residue in the hinge
region. This B7h-Ig insert was subcloned into a SalI±NotI pEGFP-in lymph nodes rather than by direct costimulation of
N3 vector and transfected into Ig2 J558L cells. A murine b7.2 cDNAnaive T cells. Further work will be required to evaluate
was subcloned into a MSCV-IRES-GFP retroviral vector with a GFPthe in vivo significance of B7h as a costimulatory ligand
marker expressed using an internal ribosomal entry sequence (Ran-in regulating normal immune responses and the extent
ganath et al., 1998). An MSCV Aad-IRES-Abd retroviral vector (gift
and potential consequences of its upregulation by TNFa of Jim Allison) was used for transducing 3T3 cells with I-Ad. High-
in inflammation and autoimmunity. titer helper-free retroviral stocks were produced and used to infect
cell lines as described (Pear et al., 1993). For infection of CHO cells,
retroviral stocks were pseudotyped with vesicular stomatitis virusExperimental Procedures
G-glycoprotein (VSV-G).
Representational Difference Analysis
RDA was performed as described in Hubank and Schatz, 1994, and RNase Protection Assays
Total cellular RNAs were prepared from cell lines and tissues usingmodified as described in Ouyang et al., 1999. RelA1/1 and RelA2/2
3T3 cells (Beg and Baltimore, 1996) were treated with 10 ng/ml Tri-Reagent (Molecular Research Center) according to manufactur-
er's protocol. Total RNA (15 mg) was used in each to analyze expres-recombinant murine TNFa (Genzyme) and used to prepare tester
and driver cDNA representations, respectively. After three rounds sion by RNase protection assays, which were performed as pre-
viously described (Sha et al., 1988). Two RNase protection probesof RDA subtraction, DpnII-digested inserts were subcloned into a
B7h, a Novel Costimulatory Ligand, Induced by TNFa
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were used to examine B7h expression. The first B7h probe (Figure spleen cells and used at day 4. Activated B cells were labeled at
day 2 by addition of 3H-thymidine to LPS-stimulated (30 mg/ml)1) corresponded to the original D30 DpnII insert (nucleotides 1309±
1660) and the second B7h probe (Figures 6 and 7) corresponded C57BL/6 spleen cells and used at day 3. Cultures were purified over
Histopaque-1119 (Sigma), and 105 cells were added to confluentto a PvuII±SmaI insert (nucleotides 243±591). Both of these inserts
were subcloned into BSSKII(-) (Stratagene), and antisense RNA CHO cells plated on 96-well flat-bottom plates.
probes were generated using T7 RNA polymerase. The B7.2 RNase
protection probe was generated by PCR from a murine b7.2 cDNA
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Fluorescent images were acquired on a Leica DMIRB/E fluores-
cence microscope and captured and processed using Slidebook
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of CHO cells and immunoprecipitations with an anti-GFP mAb
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